On September 4, 2019, Halozyme Therapeutics, Inc., a Delaware corporation (“Halozyme”), presented at the 2019 Wells Fargo Healthcare Conference to provide a corporate update on certain strategic programs. Attached hereto as Exhibit 99.1, and incorporated herein by reference, is a copy of the slides used by Halozyme in making the presentation that are expected to be used in subsequent presentations to interested parties, including analysts and stockholders.

This information is being furnished to Item 7.01 of this Report and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Halozyme, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed to Regulation FD.

Please refer to the slide deck attached as Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

Item 9.01. Financial Statements and Exhibits.

HALOZYME THERAPEUTICS, INC. Exhibit
EX-99.1 2 ex991presentation.htm EXHIBIT 99.1 ex991presentation 2019 Wells Fargo Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley,…
To view the full exhibit click here

About HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).